We utilised real-world experience to examine the prognostic value of serum albumin concentration (g/L) in patients with metastatic NSCLC receiving first-line targeted therapy or immunotherapy-based systemic anticancer therapy (SACT). This evidence concerns the gene ALB and non-small cell lung carcinoma.